Trestle Biotherapeutics Analysis: $125K Raised
What is Trestle Biotherapeutics?
Trestle Biotherapeutics develops bioengineered therapies for kidney disease, focusing on implantable tissues to enhance patient outcomes and reduce dialysis dependence.
Founded
2020
Revenue
<$5 Million
Company Stage
Seed
YC Batch
W21
Product Features & Capabilities
- implantable therapeutic tissues for end-stage renal disease, bioengineered tissues to replace dialysis, potential to delay kidney transplantation, solutions for organ failure
How much Trestle Biotherapeutics raised
1 - $125K
2021Lead Investor: Y Combinator, Formic Ventures, and 1 other
Who are the founders of Trestle Biotherapeutics
BS
Ben Shepherd
Co-Founder, CEO
AC
Alice Chen
Co-Founder, Chief Scientific Officer
Investors
- KidneyX Innovation Accelerator
- Acequia Capital (AceCap)
- Y Combinator
- Formic Ventures
- Black Mountain Ventures
- C3 Ventures
- Axial VC
- Wellcome Leap HOPE Program
